Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 127 articles:
HTML format
Text format



Single Articles


    May 2018
  1. LARIMER BM, Dubois F, Bloch E, Nesti S, et al
    Specific (18)F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models is Facilitated by Pre-Binding to Sex Hormone Binding Globulin.
    J Nucl Med. 2018 May 31. pii: jnumed.118.208785. doi: 10.2967/jnumed.118.208785.
    PubMed     Text format     Abstract available


  2. THALGOTT M, Duwel C, Rauscher I, Heck MM, et al
    One-stop shop whole-body (68)Ga-PSMA-11 PET/MRI compared to clinical Nomograms for preoperative T- and N-Staging of High-Risk Prostate Cancer.
    J Nucl Med. 2018 May 24. pii: jnumed.117.207696. doi: 10.2967/jnumed.117.207696.
    PubMed     Text format     Abstract available


  3. DOUGHTON JA, Hofman MS, Eu P, Hicks RJ, et al
    A first-in-man study of (68)Ga-nanocolloid PET-CT sentinel lymph node imaging in prostate cancer demonstrates aberrant lymphatic drainage pathways.
    J Nucl Med. 2018 May 4. pii: jnumed.118.209171. doi: 10.2967/jnumed.118.209171.
    PubMed     Text format     Abstract available


  4. ELSCHOT M, Selnaes KM, Johansen H, Kruger-Stokke B, et al
    The Effect of Including Bone in DIXON-based Attenuation Correction for (18)F-fluciclovine PET/MRI of Prostate Cancer.
    J Nucl Med. 2018 May 4. pii: jnumed.118.208868. doi: 10.2967/jnumed.118.208868.
    PubMed     Text format     Abstract available


    April 2018
  5. CALAIS J, Kishan AU, Cao M, Fendler WP, et al
    Potential impact of (68)Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.209387. doi: 10.2967/jnumed.118.209387.
    PubMed     Text format     Abstract available


  6. AHMADZADEHFAR H, Essler M
    Predictive factors of response and overall survival in patients with castration-resistant metastatic prostate cancer undergoing (177)Lu-PSMA therapy.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.209270. doi: 10.2967/jnumed.118.209270.
    PubMed     Text format    


  7. GRKOVSKI M, Gharzeddine K, Sawan P, Schoder H, et al
    (11)C-choline pharmacokinetics in recurrent prostate cancer.
    J Nucl Med. 2018 Apr 6. pii: jnumed.118.210088. doi: 10.2967/jnumed.118.210088.
    PubMed     Text format     Abstract available


  8. VARGAS HA, Kramer GM, Scott AM, Weickhardt A, et al
    Reproducibility and repeatability of semi-quantitative (18)F-fluorodihydrotestosterone (FDHT) uptake metrics in castration-resistant prostate cancer metastases: a prospective multi-center study.
    J Nucl Med. 2018 Apr 6. pii: jnumed.117.206490. doi: 10.2967/jnumed.117.206490.
    PubMed     Text format     Abstract available


    March 2018
  9. HARMON SA STEPHANIE., Bergvall E, Mena E, Shih JH, et al
    A Prospective Comparison of (18)F-Sodium Fluoride PET/CT and PSMA-targeted (18)F-DCFBC PET/CT in Metastatic Prostate Cancer.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.207373. doi: 10.2967/jnumed.117.207373.
    PubMed     Text format     Abstract available


  10. ZETTLITZ KA, Tsai WK, Knowles SM, Kobayashi N, et al
    Dual-modality immunoPET and near-infrared fluorescence (NIRF) imaging of pancreatic cancer using an anti-prostate cancer stem cell antigen (PSCA) cys-diabody.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.207332. doi: 10.2967/jnumed.117.207332.
    PubMed     Text format     Abstract available


  11. LUCKERATH K, Stuparu AD, Wei L, Kim W, et al
    Detection threshold and reproducibility of (68)Ga-PSMA11 PET/CT in a mouse model of prostate cancer.
    J Nucl Med. 2018 Mar 30. pii: jnumed.118.207704. doi: 10.2967/jnumed.118.207704.
    PubMed     Text format     Abstract available


  12. PARENT EE, Schuster DM
    Update on (18)F-fluciclovine PET for prostate cancer imaging.
    J Nucl Med. 2018 Mar 9. pii: jnumed.117.204032. doi: 10.2967/jnumed.117.204032.
    PubMed     Text format     Abstract available


  13. CALAIS J, Fendler WP, Herrmann K, Eiber M, et al
    Reply: Comparison of (68)Ga-PSMA-11 and (18)F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective trial is on its way.
    J Nucl Med. 2018 Mar 1. pii: jnumed.118.209965. doi: 10.2967/jnumed.118.209965.
    PubMed     Text format    


  14. WONDERGEM M, van der Zant F, Vlottes P, Knol R, et al
    Effects of fasting on (18)F-DCFPyL uptake in prostate cancer lesions and tissues with known high physiologic uptake.
    J Nucl Med. 2018 Mar 1. pii: jnumed.117.207316. doi: 10.2967/jnumed.117.207316.
    PubMed     Text format     Abstract available


    February 2018
  15. DENES B, Gardiner P
    Comparison of (68)Ga-PSMA-11 PET/CT and (18)F-Fluciclovone PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Interesting, but Far from Definitive.
    J Nucl Med. 2018 Feb 23. pii: jnumed.118.209817. doi: 10.2967/jnumed.118.209817.
    PubMed     Text format    


  16. GIESEL F, Will L, Kesch C, Freitag M, et al
    Biochemical recurrence of prostate cancer: initial results with (18)F-PSMA-1007 PET/CT.
    J Nucl Med. 2018 Feb 1. pii: jnumed.117.196329. doi: 10.2967/jnumed.117.196329.
    PubMed     Text format     Abstract available


    January 2018
  17. RATHKE H, Afshar-Oromieh A, Giesel FL, Kremer C, et al
    Intra-individual comparison of Tc-99m-MDP bone scan and the PSMA-ligand Tc-99m-MIP-1427 in patients with osseous metastasized prostate cancer.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.200220. doi: 10.2967/jnumed.117.200220.
    PubMed     Text format     Abstract available


  18. RISCHPLER C, Beck TI, Okamoto S, Schlitter AM, et al
    (68)Ga-PSMA-HBED-CC uptake in cervical, coeliac and sacral ganglia as an important pitfall in prostate cancer PET imaging.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.204677. doi: 10.2967/jnumed.117.204677.
    PubMed     Text format     Abstract available


  19. ROWE SP, Pomper MG, Gorin MA
    Molecular Imaging of Prostate Cancer: Choosing the Right Agent.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.206318. doi: 10.2967/jnumed.117.206318.
    PubMed     Text format    


  20. CALAIS J, Cao M, Nickols NG
    The Utility of PET/CT in External Radiation Therapy Planning of Prostate Cancer.
    J Nucl Med. 2018 Jan 4. pii: jnumed.117.196444. doi: 10.2967/jnumed.117.196444.
    PubMed     Text format     Abstract available


    December 2017
  21. GIESEL F, Will L, Lawal I, Lengana T, et al
    Intra-individual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study.
    J Nucl Med. 2017 Dec 21. pii: jnumed.117.204669. doi: 10.2967/jnumed.117.204669.
    PubMed     Text format     Abstract available


  22. CALAIS J, Fendler WP, Herrmann K, Eiber M, et al
    Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and (18)F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.203257. doi: 10.2967/jnumed.117.203257.
    PubMed     Text format     Abstract available


  23. CECI F, Fendler W, Eiber M
    A new type of prostate cancer imaging. Will (64)CuCl2 PET/CT flourish or vanish?
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.199885. doi: 10.2967/jnumed.117.199885.
    PubMed     Text format    


  24. JADVAR H, Ballas LK
    PSMA PET: Transformational Change in Prostate Cancer Management?
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.203604. doi: 10.2967/jnumed.117.203604.
    PubMed     Text format    


  25. CALAIS J, Fendler WP, Eiber M, Gartmann J, et al
    Actual impact of (68)Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.202945. doi: 10.2967/jnumed.117.202945.
    PubMed     Text format     Abstract available


    November 2017
  26. BARANSKI AC, Schafer M, Bauder-Wust U, Roscher M, et al
    PSMA-11 Derived Dual-labeled PSMA-Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.
    J Nucl Med. 2017 Nov 30. pii: jnumed.117.201293. doi: 10.2967/jnumed.117.201293.
    PubMed     Text format     Abstract available


  27. ZHANG J, Niu G, Fan X, Lang L, et al
    Positron Emission Tomography Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198929. doi: 10.2967/jnumed.117.198929.
    PubMed     Text format     Abstract available


  28. CALAIS J, Czernin J, Cao M, Kishan AU, et al
    68Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.201749. doi: 10.2967/jnumed.117.201749.
    PubMed     Text format     Abstract available


  29. EIBER M, Herrmann K, Calais J, Hadaschihk B, et al
    PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198119. doi: 10.2967/jnumed.117.198119.
    PubMed     Text format     Abstract available


  30. GIESEL FL, Kopka K
    Reply: PSMA ligands for imaging prostate cancer - alternative labeling by complex formation with Al18F.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198176. doi: 10.2967/jnumed.117.198176.
    PubMed     Text format    


    October 2017
  31. MINAMIMOTO R, Sonni I, Hancock S, Vasanawala S, et al
    Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Conventional Imaging.
    J Nucl Med. 2017 Oct 30. pii: jnumed.117.197624. doi: 10.2967/jnumed.117.197624.
    PubMed     Text format     Abstract available


  32. HOFMAN MS, Eu P, Jackson P, Hong E, et al
    Cold Kit PSMA PET Imaging: Phase I study of 68Ga-THP-PSMA PET/CT in patients with prostate cancer.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.199554. doi: 10.2967/jnumed.117.199554.
    PubMed     Text format     Abstract available


  33. ELSCHOT M, Selnaes KM, Sandsmark E, Kruger-Stokke B, et al
    Combined 18F-Fluciclovine PET/MRI shows potential for detection and characterization of high-risk prostate cancer.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.198598. doi: 10.2967/jnumed.117.198598.
    PubMed     Text format     Abstract available


  34. DONIN NM, Reiter R
    Why targeting PSMA is a game changer in the management of prostate cancer - a Urologist's point of view.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.191874. doi: 10.2967/jnumed.117.191874.
    PubMed     Text format     Abstract available


  35. KRATOCHWIL C, Bruchertseifer F, Rathke H, Bronzel M, et al
    Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.
    J Nucl Med. 2017;58:1624-1631.
    PubMed     Text format     Abstract available


    September 2017
  36. IAGARU A
    Will GRPR Compete with PSMA as a Target in Prostate Cancer?
    J Nucl Med. 2017 Sep 28. pii: jnumed.117.198192. doi: 10.2967/jnumed.117.198192.
    PubMed     Text format    


  37. FENDLER WP, Cutler C
    More alpha than beta for prostate cancer?
    J Nucl Med. 2017 Sep 21. pii: jnumed.117.198333. doi: 10.2967/jnumed.117.198333.
    PubMed     Text format    


  38. PICCARDO A, Paparo F, Puntoni M, Righi S, et al
    64CuCl2 PET/CT in prostate cancer relapse.
    J Nucl Med. 2017 Sep 8. pii: jnumed.117.195628. doi: 10.2967/jnumed.117.195628.
    PubMed     Text format     Abstract available


  39. FOSBOL MO, Petersen PM, Kjaer A, Mortensen J, et al
    Radium-223 therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematological toxicity.
    J Nucl Med. 2017 Sep 1. pii: jnumed.117.195677. doi: 10.2967/jnumed.117.195677.
    PubMed     Text format     Abstract available


  40. SANO K, Kanada Y, Kanazaki K, Ding N, et al
    Brachytherapy with Intratumoral Injections of Radiometal-Labeled Polymers That Thermoresponsively Self-Aggregate in Tumor Tissues.
    J Nucl Med. 2017;58:1380-1385.
    PubMed     Text format     Abstract available


    August 2017
  41. WOYTHAL N, Arsenic R, Kempkensteffen C, Miller K, et al
    Immunohistochemical validation of PSMA-expression measured by 68Ga-PSMA PET/CT in primary prostate cancer.
    J Nucl Med. 2017 Aug 3. pii: jnumed.117.195172. doi: 10.2967/jnumed.117.195172.
    PubMed     Text format     Abstract available


    July 2017
  42. AFAQ A, Alahmed S, Chen SH, Lengana T, et al
    68Ga-PSMA PET/CT impact on prostate cancer management.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.192625. doi: 10.2967/jnumed.117.192625.
    PubMed     Text format     Abstract available


  43. GRIVAS N, Wit E, Kuusk T, KleinJan G, et al
    The impact of adding sentinel node biopsy to extended pelvic lymph node dissection on the biochemical recurrence of prostate cancer patients treated with robot-assisted radical prostatectomy.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.195644. doi: 10.2967/jnumed.117.195644.
    PubMed     Text format     Abstract available


  44. EMMETT L EMMETTHRUB, Van Leeuwen P, Nandurkar R, Scheltema MJ, et al
    Treatment outcomes from 68GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.196683. doi: 10.2967/jnumed.117.196683.
    PubMed     Text format     Abstract available


  45. SCHWARZENBOCK SM, Rauscher I, Bluemel C, Fendler WP, et al
    PSMA Ligands for PET-Imaging of Prostate Cancer.
    J Nucl Med. 2017 Jul 7. pii: jnumed.117.191031. doi: 10.2967/jnumed.117.191031.
    PubMed     Text format     Abstract available


    June 2017
  46. FENDLER WP, Rahbar K, Herrmann K, Kratochwil C, et al
    177Lu-PSMA radioligand therapy for prostate cancer.
    J Nucl Med. 2017 Jun 29. pii: jnumed.117.191023. doi: 10.2967/jnumed.117.191023.
    PubMed     Text format     Abstract available


  47. AL-MOMANI E, Machulla HJ
    PSMA ligands for imaging prostate cancer - alternative labeling by complex formation with Al18F.
    J Nucl Med. 2017 Jun 29. pii: jnumed.117.197996. doi: 10.2967/jnumed.117.197996.
    PubMed     Text format    


  48. ROACH PJ, Francis R, Emmett L, Hsiao E, et al
    The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study.
    J Nucl Med. 2017 Jun 23. pii: jnumed.117.197160. doi: 10.2967/jnumed.117.197160.
    PubMed     Text format     Abstract available


  49. HOFMAN MS
    Accuracy in the eye of the beholder: can we improve agreement in prostate cancer diagnostics with PSMA PET/CT?
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.192542. doi: 10.2967/jnumed.117.192542.
    PubMed     Text format    


  50. VINSENSIA M, Choyke PL, Hadaschik B, Holland-Letz T, et al
    68Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.116.185033. doi: 10.2967/jnumed.116.185033.
    PubMed     Text format     Abstract available


  51. KOERBER SA, Utzinger MT, Kratochwil C, Kesch C, et al
    68Ga-PSMA11-PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters.
    J Nucl Med. 2017 Jun 15. pii: jnumed.117.190314. doi: 10.2967/jnumed.117.190314.
    PubMed     Text format     Abstract available


  52. OSMAN MM, Iravani A, Hofman MS, Hicks RJ, et al
    Detection of Synchronous Primary Malignancies with 68Ga-PSMA PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients.
    J Nucl Med. 2017 Jun 1. pii: jnumed.117.190215. doi: 10.2967/jnumed.117.190215.
    PubMed     Text format     Abstract available


    May 2017
  53. FENDLER WP, Stuparu AD, Evans-Axelsson S, Luckerath K, et al
    Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer.
    J Nucl Med. 2017 May 25. pii: jnumed.117.193359. doi: 10.2967/jnumed.117.193359.
    PubMed     Text format     Abstract available


  54. BIETH M, Kronke M, Tauber R, Dahlbender M, et al
    Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumour Burden in Prostate Cancer using 68Ga-PSMA-PET/CT.
    J Nucl Med. 2017 May 25. pii: jnumed.116.189050. doi: 10.2967/jnumed.116.189050.
    PubMed     Text format     Abstract available


  55. JACOBSON O, Chen H, Niu G, Kiesewetter DO, et al
    PET-guided evaluation and optimization of internalized antibody-drug conjugates targeting erythropoietin producing hepatoma A2 receptor.
    J Nucl Med. 2017 May 25. pii: jnumed.117.192245. doi: 10.2967/jnumed.117.192245.
    PubMed     Text format     Abstract available


  56. HOPE TA, Aggarwal R, Chee B, Tao D, et al
    Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2017 May 18. pii: jnumed.117.192476. doi: 10.2967/jnumed.117.192476.
    PubMed     Text format     Abstract available


  57. SCHMUCK S, von Klot CA, Henkenberens C, Sohns JM, et al
    Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.
    J Nucl Med. 2017 May 18. pii: jnumed.117.193581. doi: 10.2967/jnumed.117.193581.
    PubMed     Text format     Abstract available


  58. HADASCHIK B, Boegemann M
    Why Targeting PSMA is a valuable addition in the management of castration-resistant prostate cancer: The Urologists' point of view.
    J Nucl Med. 2017 May 18. pii: jnumed.117.194753. doi: 10.2967/jnumed.117.194753.
    PubMed     Text format    


  59. KESCH C, Vinsensia M, Radtke JP, Schlemmer HP, et al
    Intra-individual comparison of 18F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study.
    J Nucl Med. 2017 May 4. pii: jnumed.116.189233. doi: 10.2967/jnumed.116.189233.
    PubMed     Text format     Abstract available


    April 2017
  60. WONDERGEM M, van der Zant F, Knol R, Lazarenko S, et al
    18F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes ; detection rate, image quality, activity kinetics and biodistribution.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.192658. doi: 10.2967/jnumed.117.192658.
    PubMed     Text format     Abstract available


  61. KELLY JM, Amor-Coarasa A, Nikolopoulou A, Wustemann T, et al
    Double Targeting Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
    J Nucl Med. 2017 Apr 27. pii: jnumed.116.188722. doi: 10.2967/jnumed.116.188722.
    PubMed     Text format     Abstract available


  62. YOUNG JD, Abbate V, Imberti C, Meszaros LK, et al
    68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room temperature, one-step kit-based radiolabeling.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.191882. doi: 10.2967/jnumed.117.191882.
    PubMed     Text format     Abstract available


  63. FENDLER WP, Calais J, Allen-Auerbach M, Bluemel C, et al
    68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190827. doi: 10.2967/jnumed.117.190827.
    PubMed     Text format     Abstract available


  64. KESCH C, Kratochwil C, Mier W, Kopka K, et al
    Gallium-68 or Fluorine-18 for prostate cancer imaging?
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190157. doi: 10.2967/jnumed.117.190157.
    PubMed     Text format     Abstract available


  65. MILLER MP, Kostakoglu L, Pryma D, Yu JQ, et al
    Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine (18F) PET/CT.
    J Nucl Med. 2017 Apr 6. pii: jnumed.116.188375. doi: 10.2967/jnumed.116.188375.
    PubMed     Text format     Abstract available


    March 2017
  66. GOFFIN KE, Joniau S, Tenke P, Slawin K, et al
    Phase 2 study of 99mTc-trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic lymph node dissection.
    J Nucl Med. 2017 Mar 16. pii: jnumed.116.187807. doi: 10.2967/jnumed.116.187807.
    PubMed     Text format     Abstract available


  67. PIERT M, Shao X, Raffel DM, Davenport MS, et al
    Preclinical evaluation of 11C-sarcosine as a substrate of proton-coupled amino acid transporters and first human application in prostate cancer.
    J Nucl Med. 2017 Mar 16. pii: jnumed.116.173179. doi: 10.2967/jnumed.116.173179.
    PubMed     Text format     Abstract available


    February 2017
  68. EINSPIELER I, Rauscher I, Duwel C, Kronke M, et al
    Detection efficacy of hybrid 68Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria.
    J Nucl Med. 2017 Feb 16. pii: jnumed.116.184457. doi: 10.2967/jnumed.116.184457.
    PubMed     Text format     Abstract available


    January 2017
  69. AFSHAR-OROMIEH A, Sattler LP, Mier W, Hadaschik B, et al
    The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer.
    J Nucl Med. 2017 Jan 6. pii: jnumed.116.183483. doi: 10.2967/jnumed.116.183483.
    PubMed     Text format     Abstract available


    December 2016
  70. LI X, Rowe SP, Leal JP, Gorin MA, et al
    Quantitative Parameters in PSMA-targeted PET Imaging with 18F-DCFPyL: Variability in Normal Organ Uptake.
    J Nucl Med. 2016 Dec 8. pii: jnumed.116.179739.
    PubMed     Text format     Abstract available


  71. DIETLEIN F, Kobe C, Neubauer S, Schmidt M, et al
    PSA-stratified performance of 18F- and 68Ga-labeled tracers in PSMA-PET imaging of patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2016 Dec 1. pii: jnumed.116.185538.
    PubMed     Text format     Abstract available


    October 2016
  72. CARDINALE J, Schafer M, Benesova M, Bauder-Wust U, et al
    Preclinical Evaluation of [18F]PSMA-1007: A New PSMA-Ligand for Prostate Cancer Imaging.
    J Nucl Med. 2016 Oct 27. pii: jnumed.116.181768.
    PubMed     Text format     Abstract available


  73. RAHBAR K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, et al
    German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients.
    J Nucl Med. 2016 Oct 20. pii: jnumed.116.183194.
    PubMed     Text format     Abstract available


  74. KULKARNI HR, Singh A, Schuchardt C, Niepsch K, et al
    PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  75. ROWE SP, Drzezga A, Neumaier B, Dietlein M, et al
    Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  76. AFSHAR-OROMIEH A, Babich JW, Kratochwil C, Giesel FL, et al
    The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  77. PANDIT-TASKAR N, Veach DR, Fox JJ, Scher HI, et al
    Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  78. BALLAS LK, de Castro Abreu AL, Quinn DI
    What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  79. MANSI R, Minamimoto R, Macke H, Iagaru AH, et al
    Bombesin-Targeted PET of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  80. SCHUSTER DM, Nanni C, Fanti S
    Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  81. BEHESHTI M, Rezaee A, Geinitz H, Loidl W, et al
    Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  82. CECI F, Castellucci P, Mapelli P, Incerti E, et al
    Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  83. MAPELLI P, Incerti E, Ceci F, Castellucci P, et al
    11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  84. WEBER WA, Morris MJ
    Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format    


  85. NITSCH S, Hakenberg OW, Heuschkel M, Drager D, et al
    Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  86. SPICK C, Herrmann K, Czernin J
    Evaluation of Prostate Cancer with 11C-Acetate PET/CT.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  87. JADVAR H
    PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  88. JADVAR H
    Radiotheranostics in Prostate Cancer: Introduction and Overview.
    J Nucl Med. 2016;57.
    PubMed     Text format    


  89. IAGARU AH, Mittra E, Colletti PM, Jadvar H, et al
    Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  90. CHEN FK, de Castro Abreu AL, Palmer SL
    Utility of Ultrasound in the Diagnosis, Treatment, and Follow-up of Prostate Cancer: State of the Art.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  91. LINDENBERG L, Ahlman M, Turkbey B, Mena E, et al
    Evaluation of Prostate Cancer with PET/MRI.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


  92. KILCOYNE A, Harisinghani MG, Mahmood U
    Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles.
    J Nucl Med. 2016;57.
    PubMed     Text format     Abstract available


    September 2016
  93. AHMADZADEHFAR H, Azgomi K, Hauser S, Wei X, et al
    68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.178533.
    PubMed     Text format     Abstract available


  94. OKAMOTO S, Thieme A, Allmann J, D'Alessandria C, et al
    Radiation dosimetry for 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.178483.
    PubMed     Text format     Abstract available


  95. HOPE TA, Truillet CC, Ehman EC, Afshar-Oromieh A, et al
    Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.181800.
    PubMed     Text format     Abstract available


  96. ROBU S, Schottelius M, Eiber M, Maurer T, et al
    Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer.
    J Nucl Med. 2016 Sep 15. pii: jnumed.116.178939.
    PubMed     Text format     Abstract available


  97. JANI A, Schreibmann E, Rossi PJ, Shelton JW, et al
    Impact of Fluciclovine (18F) Positron Emission Tomography on Target Volume Definition for Post-Prostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial.
    J Nucl Med. 2016 Sep 8. pii: jnumed.116.176057.
    PubMed     Text format     Abstract available


  98. FERDINANDUS J, Eppard E, Gartner F, Kurpig S, et al
    Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617.
    J Nucl Med. 2016 Sep 1. pii: jnumed.116.178228.
    PubMed     Text format     Abstract available


    August 2016
  99. OYEN WJ, de Bono JS
    Targeted alpha-based treatment of metastatic castration-resistant prostate cancer patients: revolutionizing systemic radiotherapy?
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.179887.
    PubMed     Text format    


  100. DE BOER P, Piet AH, Oprea-Lager DE, Slotman B, et al
    Letter: PET-guided stereotactic irradiation of prostate cancer lymph node metastases.
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.181149.
    PubMed     Text format    


  101. D'SOUZA JW, Hensley H, Doss M, Beigarten C, et al
    Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-based Positron Emission Tomography Radiotracers.
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.178780.
    PubMed     Text format     Abstract available


  102. PANDIT-TASKAR N, O'Donoghue JA, Ruan S, Lyashchenko S, et al
    First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
    J Nucl Med. 2016 Aug 11. pii: jnumed.116.176206.
    PubMed     Text format     Abstract available


  103. ZHANG H, Desai P, Koike Y, Houghton J, et al
    Dual modality imaging of prostate cancer with a fluorescent and radiogallium-labeled GRP receptor antagonist.
    J Nucl Med. 2016 Aug 11. pii: jnumed.116.176099.
    PubMed     Text format     Abstract available


  104. NOCK BA, Kaloudi A, Lymperis E, Giarika A, et al
    Theranostic perspectives in prostate cancer with the GRPR-antagonist NeoBOMB1 - Preclinical and first clinical results.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.178889.
    PubMed     Text format     Abstract available


  105. ZHANG J, Niu G, Lang L, Li F, et al
    Clinical translation of a dual integrin alphavbeta3 and GRPR targeting PET radiotracer 68Ga-NOTA-BBN-RGD.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.177048.
    PubMed     Text format     Abstract available


    July 2016
  106. LIN C, Bradshaw TJ, Perk TG, Harmon S, et al
    Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
    J Nucl Med. 2016 Jul 21. pii: jnumed.116.177295.
    PubMed     Text format     Abstract available


  107. HARADA N, Kimura H, Onoe S, Watanabe H, et al
    Synthesis and Biological Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for Positron Emission Tomography of Prostate Cancer.
    J Nucl Med. 2016 Jul 14. pii: jnumed.116.175810.
    PubMed     Text format     Abstract available


  108. KRATOCHWIL C, Bruchertseifer F, Giesel FL, Weis M, et al
    225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2016 Jul 7. pii: jnumed.116.178673.
    PubMed     Text format     Abstract available


    June 2016
  109. RAUSCHER I, Maurer T, Beer AJ, Graner FP, et al
    Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy.
    J Nucl Med. 2016 Jun 3. pii: jnumed.116.173492.
    PubMed     Text format     Abstract available


  110. FENDLER WP, Schmidt DF, Wenter V, Thierfelder KM, et al
    68Ga-PSMA-HBED-CC PET/CT detects location and extent of primary prostate cancer.
    J Nucl Med. 2016 Jun 3. pii: jnumed.116.172627.
    PubMed     Text format     Abstract available


    May 2016
  111. CYSOUW MC, Kramer GM, Hoekstra OS, Frings V, et al
    Accuracy and precision of partial volume correction in oncological PET/CT studies.
    J Nucl Med. 2016 May 26. pii: jnumed.116.173831.
    PubMed     Text format     Abstract available


    April 2016
  112. RAHBAR K, Schmidt M, Heinzel A, Eppard E, et al
    Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis.
    J Nucl Med. 2016 Apr 7. pii: jnumed.116.173757.
    PubMed     Text format     Abstract available


    March 2016
  113. KRATOCHWIL C, Giesel FL, Stefanova M, Benesova M, et al
    PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.171397.
    PubMed     Text format     Abstract available


  114. PIERT M, Montgomery J, Kunju LP, Siddiqui J, et al
    18F-choline PET/MRI: the Additional Value of PET for MRI-guided Transrectal Prostate Biopsies.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.170878.
    PubMed     Text format     Abstract available


    February 2016
  115. KWEKKEBOOM DJ
    Perspective on 177Lu-PSMA therapy of metastatic castration-resistant prostate cancer.
    J Nucl Med. 2016 Feb 18. pii: jnumed.115.171363.
    PubMed     Text format    


  116. LEE JH, Sato M, Coel MN, Lee KH, et al
    Prediction of PSA Progression in Castrate-Resistant Prostate Cancer based on Treatment-Associated Change in Tumor Burden Quantified by 18F-fluorocholine PET/CT.
    J Nucl Med. 2016 Feb 16. pii: jnumed.115.169177.
    PubMed     Text format     Abstract available


    January 2016
  117. APOLO AB, Lindenberg L, Shih JH, Mena E, et al
    Prospective Study Evaluating Na18F-Positron Emission Tomography/Computed Tomography (NaF-PET/CT) in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.
    J Nucl Med. 2016 Jan 21. pii: jnumed.115.166512.
    PubMed     Text format     Abstract available


  118. BAUM RP, Kulkarni HR, Schuchardt C, Singh A, et al
    Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    J Nucl Med. 2016 Jan 21. pii: jnumed.115.168443.
    PubMed     Text format     Abstract available


  119. RAHBAR K, Weckesser M, Huss S, Semjonow A, et al
    Correlation of intraprostatic tumor extent with 68-Ga-PSMA distribution in patients with prostate cancer.
    J Nucl Med. 2016 Jan 14. pii: jnumed.115.169243.
    PubMed     Text format     Abstract available


  120. LARSON SM
    EXINI Quantitative Bone Scan Index: Expanded Utility for the Planar Radionuclide Bone Scan.
    J Nucl Med. 2016;57:5-6.
    PubMed     Text format    


    December 2015
  121. OPREA-LAGER DE, Kramer G, van de Ven P, van den Eertwegh A, et al
    Repeatability of quantitative 18F-fluoromethylcholine PET/CT studies in prostate cancer.
    J Nucl Med. 2015 Dec 23. pii: jnumed.115.167692.
    PubMed     Text format     Abstract available


  122. MINAMIMOTO R, Hancock S, Schneider B, Chin F, et al
    Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA PET in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2015 Dec 10. pii: jnumed.115.168393.
    PubMed     Text format     Abstract available


    November 2015
  123. PYKA T, Weirich G, Einspieler I, Maurer T, et al
    [68Ga]PSMA-HBED PET for differential diagnosis of suspicious lung lesions in patients with prostate cancer.
    J Nucl Med. 2015 Nov 19. pii: jnumed.115.164442.
    PubMed     Text format     Abstract available


  124. VERWER EE, Lammertsma AA, Boellaard R
    Reply: Simplified Methods for Quantification of 18F-Fluoromethylcholine Uptake: Is SUVAUC,PP Actually an SUV?
    J Nucl Med. 2015;56:1806-7.
    PubMed     Text format    


  125. LAFFON E, de Clermont H, Marthan R
    Simplified Methods for Quantification of 18F-Fluoromethylcholine Uptake: Is SUVAUC,PP Actually an SUV?
    J Nucl Med. 2015;56:1806.
    PubMed     Text format    


    September 2015
  126. MINAMIMOTO R, Loening A, Jamali M, Barkhodari A, et al
    Prospective Comparison of 99mTc MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT and Whole-Body MRI in Patients with Breast and Prostate Cancers.
    J Nucl Med. 2015 Sep 24. pii: jnumed.115.162610.
    PubMed     Text format     Abstract available


    July 2015
  127. KIESS A, Minn I, Chen Y, Hobbs RF, et al
    Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
    J Nucl Med. 2015 Jul 16. pii: jnumed.115.155929.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: